{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:41:46Z","timestamp":1792233706632,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.08.004","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:11:17Z","timestamp":1789139477000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial"],"prefix":"10.1016","author":[{"given":"Yanxiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiman","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jval.2026.08.004_bib1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jval.2026.08.004_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10585-024-10305-2","article-title":"Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics","volume":"41","author":"Elbahoty","year":"2024","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"10.1016\/j.jval.2026.08.004_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.21320\/2500-2139-2023-16-3-229-241","article-title":"Perspectives for the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma","volume":"16","author":"Semochkin","year":"2024","journal-title":"Clin Oncohematol"},{"issue":"15","key":"10.1016\/j.jval.2026.08.004_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71093","article-title":"Real-world treatment patterns and outcomes in patients with relapsed\/refractory multiple myeloma and 1-3 prior lines of therapy: Optum database","volume":"14","author":"Dhakal","year":"2025","journal-title":"Cancer Med"},{"issue":"15","key":"10.1016\/j.jval.2026.08.004_bib5","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3390\/cancers17071168","article-title":"Forcing ahead: second-line treatment options for lenalidomide-refractory multiple myeloma","volume":"17","author":"Mancuso","year":"2025","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jval.2026.08.004_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ajh.27206","article-title":"Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the phase 2 study DARIA","volume":"99","author":"Terpos","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jval.2026.08.004_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma","volume":"11","author":"Lecat","year":"2021","journal-title":"Front Oncol"},{"issue":"suppl 3","key":"10.1016\/j.jval.2026.08.004_bib8","article-title":"Real-world patient characteristics and survival outcomes of lenalidomide refractory vs. lenalidomide-exposed RRMM patients in the HONEUR federated data network","volume":"7","author":"Spicka","year":"2023","journal-title":"Hemasphere"},{"issue":"S2 suppl 1","key":"10.1016\/j.jval.2026.08.004_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.HS9.0000936268.48048.d9","article-title":"Analysis of daratumumab clinical trials: characteristics and outcomes in patients with lenalidomide-refractory relapsed\/refractory multiple myeloma treated with 1-3 prior lines of therapy","volume":"7","author":"Einsele","year":"2023","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.jval.2026.08.004_bib10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","article-title":"Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma","volume":"22","author":"Dimopoulos","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jval.2026.08.004_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cancers15010155","article-title":"How to manage patients with lenalidomide-refractory multiple myeloma","volume":"15","author":"de Arriba de la Fuente","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.jval.2026.08.004_bib12","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.jval.2026.08.004_bib13","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1021\/acs.bioconjchem.4c00497","article-title":"Pharmacokinetic positron emission tomography imaging of an optimized CD38-targeted 68Ga-labeled peptide in multiple myeloma: a pilot study","volume":"35","author":"Yang","year":"2024","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.jval.2026.08.004_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CAD.0000000000001520","article-title":"Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma","volume":"35","author":"Alhaj Moustafa","year":"2023","journal-title":"Anti-Cancer Drugs"},{"issue":"6","key":"10.1016\/j.jval.2026.08.004_bib15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (Apollo): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2026.08.004_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exphem.2022.07.303","article-title":"Efficacy and safety of replacing lenalidomide with pomalidomide for patients with multiple myeloma refractory to a lenalidomide-containing combination regimen","volume":"114","author":"Afari","year":"2022","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.jval.2026.08.004_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14712598.2024.2352591","article-title":"Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma","volume":"24","author":"Jagannath","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.jval.2026.08.004_bib18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2026.08.004_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2014Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.jval.2026.08.004_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.jval.2026.08.004_bib21","first-page":"CS356116","article-title":"Mortality in the United States, 2023","volume":"521","author":"Murphy","year":"2024","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.jval.2026.08.004_bib22","series-title":"Recommendations for Conducting, Reporting, and Editing Cost-Effectiveness Analyses","year":"2022"},{"key":"10.1016\/j.jval.2026.08.004_bib23","series-title":"ICER Value Assessment Framework","year":"2023"},{"issue":"11","key":"10.1016\/j.jval.2026.08.004_bib24","first-page":"863","article-title":"Malignancies after chimeric antigen receptor T cell therapy","volume":"31","author":"Mohty","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.jval.2026.08.004_bib25","first-page":"408","article-title":"Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4","volume":"15","author":"Hansen","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jval.2026.08.004_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221142945","article-title":"Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma","volume":"30","author":"Kapinos","year":"2023","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.jval.2026.08.004_bib27","article-title":"Cost-effectiveness of anti-BCMA chimeric antigen receptor T cell therapy in relapsed\/refractory multiple myeloma","volume":"30","author":"Yamamoto","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.jval.2026.08.004_bib28","series-title":"CADTH Reimbursement Review: Ciltacabtagene Autoleucel (Carvykti)","year":"2024"},{"issue":"19","key":"10.1016\/j.jval.2026.08.004_bib29","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.2217\/fon-2022-0162","article-title":"Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"18","author":"Hoda","year":"2022","journal-title":"Future Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526026367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526026367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:49:41Z","timestamp":1792230581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526026367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S1098301526026367"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.08.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}